Alkem Laboratories Q2 profit falls 12% YoY to ₹675 crore, EBITDA grows 22%; board appoints new CFO

In the corresponding period of the preceding fiscal year, the pharmaceutical company had logged a profit of ₹765.06 crore, according to a regulatory filing.

Sequentially, however, its profit surged 29.88% quarter-on-quarter (QoQ) from ₹519.96 crore in the first quarter of the current fiscal year (Q1 FY27).

The firm saw its consolidated revenue from operations grow 13.77% YoY to ₹4,551.99 crore during the quarter under review, compared with ₹4,000.99 crore in the same quarter of the preceding fiscal year.

The revenue surged 21.7% QoQ from ₹3,740.15 crore in the quarter-ago period.

Margin contracts

On an operational basis, its EBITDA (earnings before interest, tax, depreciation and amortisation), also known as operating profit, stood at ₹1,025.2 crore in Q2 FY27, registering a 22.5% YoY growth from ₹920.8 crore in the same quarter last year.

However, its EBITDA margin contracted by 50 basis points (bps) YoY to 22.5% for the reporting quarter, as against 23% in Q2 FY26.

India sales grow 9.5% YoY

Its India sales stood at ₹3,027.5 crore in the July to September quarter of FY27, marking a 9.5% YoY increase.

Alkem Labs recorded a 22.3% YoY growth in its international sales to ₹1,454 crore for the reporting period.

Its biotech sales fell by 35% YoY to ₹70.4 crore in the quarter ended September 30, 2026, while its MedTech sales, including Occlutech, stood at ₹133 crore.

Occlutech was integrated into the MedTech business from Q2FY27 onwards, the firm noted.

Domestic business soars 14% YoY

The contribution of domestic sales to Alkem Lab’s total sales fell to 68% in Q2 FY27, in contrast to 70% in Q2 FY26.

Furthermore, the domestic business advanced 13.8% YoY during the quarter, at par with the growth of 13.8% logged by the Indian Pharmaceutical Market, it said, citing data from IQVIA (SSA) for Q2 FY27.

The acute segment reported growth of 12.1%, at par with IPM growth of 12.3%, while the chronic segment posted growth of 22.4% versus IPM, which grew by 16%, outperforming by over 640 bps.

US sales rise 2% YoY

Its sales from the US grew 2.4% YoY to ₹783 crore in the September quarter of FY27, with US business sales contributing 17% to total sales, as compared to 19% in the year-ago period.

Its non-US sales surged 58% YoY to ₹671 crore and contributed 15% to total sales in Q2 FY27, as against 11% in the second quarter of the previous fiscal year.

New CFO appointed

Alkem Laboratories’ board of directors also appointed Gopal Kothari as the Chief Financial Officer (CFO) and Key Managerial Personnel of the company, with effect from December 2, 2026.

What the management said

Commenting on the earnings, Sandeep Singh, MD of Alkem, said: “Our Q2 FY27 performance reflects continued momentum in the India business, supported by focused execution across our acute and chronic portfolios. The international business delivered steady progress despite continued pricing pressure in the US, with volume growth providing support.”

During the quarter, he further stated that the company also expanded its MedTech presence through the addition of Occlutech, while improving execution and operating performance at Enzene remains a key priority.

“We will continue to focus on strengthening our core business, improving productivity and deploying capital prudently to build sustainable growth across pharmaceuticals, biotech and MedTech,” Singh added.

Shares of Alkem Labs fell as much as 5.05% to hit an intraday low of ₹5,173 per unit on the National Stock Exchange (NSE) on Thursday, November 12, following the earnings announcement.

Alkem Laboratories has a total market capitalisation of ₹62,891.19 crore as of November 12, 2026, according to data on the NSE.